In addition, PD-L1 expression and CD8+ T-cell infiltration were increased in the tumor microenvironment after treatment with the targeted drug anti-VEGFR2 antibody RAM in GC, and PD-1 expression in eTregs cells and CD8+ T cells was significantly reduced in TILs (136). This evidence concerns the gene PDCD1 and neoplasm.